Urology Research & Practice

MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy


Division of Diagnostic Imaging, Department of Medicine and Surgery, University of Perugia, Santa Maria della Misericordia Hospital, Perugia, Italy


Division of Urology, Nuovo Ospedale Civile Sassuolo, Modena, Italy


Division of Urology, Portogruaro Hospital, Venice, Italy


Division of Radiology, ASL, Caserta, Italy


Radiation Division of Radiology, Ospedale Santa Maria, Terni, Italy


Department of Oncology, Oncology Unit, S. Luca Hospital, Lucca, Italy


Division of Radiology, Tivoli Hospital, Tivoli, Italy


Department of Radiotherapy, Ospedale Santa Maria, Terni, Italy

Urol Res Pract 2021; 47: 448-451
DOI: 10.5152/tud.2021.21274
Read: 620 Downloads: 245 Published: 01 November 2021

Prostate specific antigen (PSA) remains the most used test to assess the response after therapies including the radiation therapy (RT). Apparent diffusion coefficient (ADC) derived from the conventional diffusionweighted imaging (DWI), as a part of noncontrast or biparametric MRI (bpMRI) (T2-weighted and DWI), offers diagnostic accuracy and cancer detection rate equivalent to that of multiparametric MRI. Cellular changes induced by RT can be quali-qualitatively demonstrated as early as 3months after RT as an increase in the signal intensity of the tumor on the ADC map. ADC, in association with PSA, represents a potential biomarker imaging for evaluating treatment efficacy in PCa both during and shortly after RT.

Cite this article as: Scialpi M, Martorana E, Scialpi P, et al. MRI apparent diffusion coefficient (ADC): A biomarker for prostate cancer after radiation therapy. Turk J Urol. 2021; 47(6): 448-451

EISSN 2980-1478